United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares after option exercise
Rhea-AI Filing Summary
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, through family trusts exercised 9,500 stock options at $135.42 and sold 9,500 shares of common stock on August 3, 2026 at weighted-average prices between $514.83 and $518.61, under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust held 217,910 options expiring March 15, 2027, while Rothblatt held 40,513 shares directly and 166 shares indirectly via a spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.62M approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.90M)
Approx. gross sale proceeds
$4.90M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.62M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F11 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 1,667 | $514.8327 | $858K |
| Sale | Common Stock F1, F4, F2 | 4,218 | $515.7276 | $2.18M |
| Sale | Common Stock F1, F5, F2 | 2,075 | $516.4895 | $1.07M |
| Sale | Common Stock F1, F6, F2 | 1,220 | $517.4859 | $631K |
| Sale | Common Stock F1, F7, F2 | 320 | $518.6113 | $166K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F8 | -- | -- | -- |
| holding | Common Stock F9 | -- | -- | -- |
| holding | Common Stock F10 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 217,910 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (11)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F11. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $514.21 to $515.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $515.22 to $516.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $516.22 to $517.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $517.22 to $518.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $518.32 to $518.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F9. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Key Figures
Options exercised: 9,500 shares
Exercise price: $135.42 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 shares
Stock options exercised on August 3, 2026 at $135.42 per share
Exercise price
$135.42 per share
Conversion or exercise price of the reported stock options
Shares sold
9,500 shares
Total common shares sold on August 3, 2026 by family trusts
Sale price range
$514.83–$518.61 per share
Weighted-average prices of the reported common stock sales
Options remaining
217,910 options
Stock options held indirectly by a family trust after the exercise
Direct common holdings
40,513 shares
Common shares held directly by the reporting person after transactions
Spouse indirect holdings
166 shares
Common shares held indirectly via spouse after transactions
10b5-1 plan options
1,734,410 options
Stock options subject to the 10b5-1 plan expiring March 15, 2027
Key Terms
10b5-1 trading plan, weighted average price, stock options, family trusts
4 terms
10b5-1 trading plan financial
"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did United Therapeutics (UTHR) CEO Martine Rothblatt report?
Martine Rothblatt reported an option exercise and related share sales. She exercised 9,500 stock options at $135.42 and sold 9,500 common shares on August 3, 2026 through family trusts at weighted-average prices between $514.83 and $518.61 per share.
Were the UTHR insider trades made under a 10b5-1 trading plan?
Yes, the option exercise and share sales were made under a 10b5-1 trading plan. A footnote states the transactions were pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until certain option exercises or December 31, 2026.
What stock options does the United Therapeutics (UTHR) CEO still hold after these trades?
A family trust held 217,910 stock options after the reported exercise. These options, referenced in the filing, have an exercise price of $135.42 per share and expire on March 15, 2027, indicating a substantial remaining option position following the 9,500-share exercise.
What is the size of the 10b5-1 plan covering UTHR options?
The 10b5-1 plan covers up to 1,734,410 stock options. According to a footnote, the plan runs until the earlier of the exercise of 1,734,410 options, all expiring on March 15, 2027, or December 31, 2026, framing the potential future activity.